- Home
- NTRB vs IKNA Comparison
NTRB vs IKNA Comparison
Compare NTRB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- IKNA
- Stock Information
- Founded
- NTRB 2016
- IKNA 2016
- Country
- NTRB United States
- IKNA United States
- Employees
- NTRB N/A
- IKNA N/A
- Industry
- NTRB Industrial Specialties
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- IKNA Health Care
- Exchange
- NTRB Nasdaq
- IKNA Nasdaq
- Market Cap
- NTRB 77.9M
- IKNA 83.0M
- IPO Year
- NTRB N/A
- IKNA 2021
- Fundamental
- Price
- NTRB $6.17
- IKNA $1.68
- Analyst Decision
- NTRB
- IKNA Buy
- Analyst Count
- NTRB 0
- IKNA 2
- Target Price
- NTRB N/A
- IKNA $3.00
- AVG Volume (30 Days)
- NTRB 28.2K
- IKNA 41.6K
- Earning Date
- NTRB 12-11-2024
- IKNA 11-07-2024
- Dividend Yield
- NTRB N/A
- IKNA N/A
- EPS Growth
- NTRB N/A
- IKNA N/A
- EPS
- NTRB N/A
- IKNA N/A
- Revenue
- NTRB $1,803,816.00
- IKNA $1,844,000.00
- Revenue This Year
- NTRB N/A
- IKNA N/A
- Revenue Next Year
- NTRB N/A
- IKNA N/A
- P/E Ratio
- NTRB N/A
- IKNA N/A
- Revenue Growth
- NTRB N/A
- IKNA N/A
- 52 Week Low
- NTRB $1.93
- IKNA $1.02
- 52 Week High
- NTRB $9.60
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- IKNA 51.57
- Support Level
- NTRB $5.24
- IKNA $1.68
- Resistance Level
- NTRB $6.40
- IKNA $1.78
- Average True Range (ATR)
- NTRB 0.71
- IKNA 0.04
- MACD
- NTRB -0.12
- IKNA 0.00
- Stochastic Oscillator
- NTRB 33.23
- IKNA 36.36
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.